NEW YORK, April 24, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on VCEL, VKTX, VTGN, and ZIOP which can be accessed for free by signing up to www.wallstequities.com/registration. On Monday, benchmark US indices were mixed as the NASDAQ Composite closed the trading session down 0.25%; the Dow Jones Industrial Average edged 0.06% lower; and the S&P 500 was up 0.01%. US markets saw five out of nine sectors finishing the day in red, three in green, and one in neutral territory. Pre-market today, WallStEquities.com reviews these four Biotechnology stocks: Vericel Corp. (NASDAQ: VCEL), Viking Therapeutics Inc. (NASDAQ: VKTX), VistaGen Therapeutics Inc. (NASDAQ: VTGN), and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). All you have to do is sign up today for this free limited time offer by clicking the link below. www.wallstequities.com/registration
Cambridge, Massachusetts headquartered Vericel Corp.'s stock finished Monday's session 2.12% higher at $12.05. A total volume of 456,725 shares was traded. The Company's shares have advanced 13.68% in the past month, 75.91% over the previous three months, and 363.46% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 20.42% and 100.59%, respectively. Furthermore, shares of Vericel, which researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs, have a Relative Strength Index (RSI) of 61.36.
On April 04th, 2018, research firm Leerink Partners initiated an 'Outperform' rating on the Company's stock, with a target price of $15 per share. Get the full research report on VCEL for free by clicking below at: www.wallstequities.com/registration/?symbol=VCEL
Shares in San Diego, California headquartered Viking Therapeutics Inc. ended at $4.29, down 8.92% from the last trading session. The stock recorded a trading volume of 832,767 shares. The Company's shares have gained 208.94% in the last twelve months. The stock is trading above its 200-day moving average by 29.99%. Moreover, shares of Viking Therapeutics, which focuses on the development of novel therapies for metabolic and endocrine disorders, have an RSI of 34.84.
On March 26th, 2018, research firm H.C. Wainwright resumed its 'Buy' rating on the Company's stock, with a target price of $11 per share. VKTX's complimentary research coverage is a few simple steps away at: www.wallstequities.com/registration/?symbol=VKTX
South San Francisco, California headquartered VistaGen Therapeutics Inc.'s stock ended yesterday's session 5.84% lower at $0.88 with a total trading volume of 544,588 shares. The stock is trading below its 50-day moving average by 23.97%. Additionally, shares of VistaGen Therapeutics, which engages in developing and commercializing medicines for depression and other central nervous system disorders, have an RSI of 34.49. Are you already registered with Wall St. Equities? Do so now for free, and get the report on VTGN at: www.wallstequities.com/registration/?symbol=VTGN
On Monday, shares in Boston, Massachusetts headquartered ZIOPHARM Oncology Inc. recorded a trading volume of 1.05 million shares. The stock finished the day 0.70% higher at $4.34. The Company's shares have advanced 3.58% in the last month. The stock is trading above its 50-day moving average by 4.95%. Furthermore, shares of ZIOPHARM Oncology, which focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens, have an RSI of 53.16. Aspiring Member, please take a moment to register below for your free research report on ZIOP at: www.wallstequities.com/registration/?symbol=ZIOP
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities